clinical trial · NCT07926048
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Qilu Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 420
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerQLS5132Liposomal DoxorubicinPaclitaxelTopotecan
brief summary
The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
started
Dec 1, 2026
primary completion
Dec 1, 2029
completion
Jan 1, 2030
last updated
Nov 9, 2026
official title
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of QLS5132 Versus Investigator's Choice of Chemotherapy in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol